ABSTRACT
BACKGROUND: Between October 2016 and March 2019, Lynn Community Health Center in Massachusetts implemented a targeted latent TB infection testing and treatment (TTT) program, increasing testing from a baseline of 1,200 patients tested to an average of 3,531 patients tested, or 9% of the population per year.METHODS: We compared pre-implementation TTT, represented by the first two quarters of implementation data, to TTT, represented by 12 quarters of data. Time, diagnostic, and laboratory resources were estimated using micro-costing. Other cost and testing data were obtained from the electronic health record, pharmaceutical claims, and published reimbursement rates. A Markov cohort model estimated future health outcomes and cost-effectiveness from a societal perspective in 2020 US dollars. Monte Carlo simulation generated 95% uncertainty intervals.RESULTS: The TTT program exhibited extended dominance over baseline pre-intervention testing and had an incremental cost-effectiveness ratio (ICER) of US$52,603 (US$22,008â-"US$95,360). When compared to baseline pre-TTT testing, the TTT program averted an estimated additional 7.12 TB cases, 3.49 hospitalizations, and 0.16 deaths per lifetime cohort each year.CONCLUSIONS: TTT was more cost-effective than baseline pre-implementation testing. Lynn Community Health Centerâ-™s experience can help inform other clinics considering expanding latent TB infection testing.
Subject(s)
Latent Tuberculosis , Tuberculosis , Humans , Tuberculosis/epidemiology , Latent Tuberculosis/diagnosis , Latent Tuberculosis/drug therapy , Latent Tuberculosis/epidemiology , Cost-Benefit Analysis , Hospitalization , Massachusetts/epidemiologyABSTRACT
BACKGROUND: Protamine is currently the most widely used drug for the reversal of heparin anticoagulation. Heparinase 1 (heparinase) is being evaluated as a possible alternative to protamine for the reversal of heparin anticoagulation. The authors evaluated the effects of equivalent doses of heparinase and protamine on platelet reactivity by measuring agonist-induced P-selectin expression. METHODS: After Institutional Review Board (IRB) approval, informed consent was obtained from 12 healthy volunteers and 8 patients undergoing surgery requiring cardiopulmonary bypass (CPB). Twenty-four ml of blood was obtained from each volunteer; 10 ml of blood was obtained from each patient before the CPB, and another 10 ml was obtained after CPB. Heparin was neutralized using heparinase or protamine. Platelet reactivity was assessed by measuring the expression of P-selectin after stimulation of platelets with increasing concentrations of a thrombin receptor agonist peptide (TRAP). Data were analyzed using analysis of variance. P < 0.05 was considered significant. RESULTS: For the healthy volunteers, the activated coagulation times (ACTs) of the heparinized samples returned to baseline values with heparinase (12.5 U/ml) or protamine (32.5 microg/ml). For the 8 patients, the ACTs returned to baseline with heparinase (20 U/ml) or protamine (50 microg/ml). The authors found no difference in the expression of P-selectin in samples neutralized with heparinase, but samples neutralized with protamine showed a significant decrease in the expression of P-selectin when compared with heparinized samples. CONCLUSIONS: At dosages that reverse the anticoagulant effects of heparin, heparinase has minimal effects on platelets, whereas platelet reactivity was markedly inhibited by protamine.
Subject(s)
Blood Platelets/drug effects , Heparin Antagonists/pharmacology , Polysaccharide-Lyases/pharmacology , Protamines/pharmacology , Adult , Animals , Blood Coagulation/drug effects , Blood Platelets/physiology , Cardiopulmonary Bypass , Cattle , Drug Interactions , Evaluation Studies as Topic , Female , Heparin Lyase , Humans , Male , Platelet Activation/drug effectsABSTRACT
The activated coagulation (clotting) time (ACT) is widely used to monitor heparin therapy during cardiopulmonary bypass (CPB). Since thrombocytopenia occurs during and for some time after CPB, we considered the possibility that thrombocytopenia may affect the ACT. Blood samples were obtained from 12 healthy volunteers. Thrombocytopenic samples were created by a differential centrifugation technique. Blood samples from five thrombocytopenic patients were also studied. The platelet counts of the control citrated whole blood samples were 254,000 +/- 35,000/microL (mean +/- SD), whereas the platelet counts of the thrombocytopenic citrated samples were 49,000 +/- 8000/microL. There were no significant differences in the ACTs between these two groups (143 +/- 8 vs 145 +/- 9 s, respectively, P = 0.16). There were also no significant differences in the ACTs of the heparinized control samples compared with the ACTs of the heparinized thrombocytopenic samples. The platelet counts of the five thrombocytopenic patients were 43,000, 18,000, 16,000, 8000, and 7000/microL, and the ACTs of the unanticoagulated samples were 162, 240, 191, 210, and 215s, respectively. We conclude that the ACT is not affected by moderate thrombocytopenia and therefore this test may be used in patients who are moderately thrombocytopenic.
Subject(s)
Thrombocytopenia/physiopathology , Whole Blood Coagulation Time , Anticoagulants/administration & dosage , Anticoagulants/blood , Anticoagulants/therapeutic use , Cardiopulmonary Bypass , Centrifugation , Hematocrit , Heparin/administration & dosage , Heparin/blood , Heparin/therapeutic use , Humans , Partial Thromboplastin Time , Platelet Count , Prothrombin Time , Thrombocytopenia/bloodABSTRACT
Thirty-five patients with suspected internal derangements of the knee were examined with conventional two-dimensional (2D) spin-echo magnetic resonance (MR) imaging techniques and a new rapid three-dimensional (3D) method called 3D FASTER (field echo acquisition with a short repetition time and echo reduction). A 9-minute 3D FASTER data acquisition achieves nearly isotropic voxels for the calculation of any desired image plane without a significant loss in image quality. Image contrast is optimized for visualization of knee anatomy in a single sequence. An image-processing workstation is used to speed the multiplanar image calculation and display for more efficient analysis of the complex 3D data set. The 3D FASTER images were superior or equal to 2D images (which took three times longer to acquire) in demonstrating meniscal tears, ligament tears, bone marrow disease, and osteochondral defects. The combined advantages of improved imaging capability and efficiency could make 3D FASTER imaging a routine MR method for knee imaging.